Bayer sets date for Q2 earnings, shares watched ahead of litigation updates

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-29, 13:22.

Bayer (DE000BAY0017) has reaffirmed its financial calendar with second-quarter 2026 results scheduled for 2026-08-07, according to its investor relations page. The DAX-listed healthcare and crop-science group remains in focus as investors assess cash flow prospects and ongoing U.S. Roundup litigation exposure.

Upcoming Q2 release and guidance focus

Per the companys financial calendar, Bayer plans to publish its Q2 2026 results and hold a conference call with analysts on 2026-08-07, including updates on Pharmaceuticals, Consumer Health and Crop Science segments. The Bayer financial calendar confirms the date and format of the release.

Investors will watch closely for any adjustments to the 2026 outlook after the company reiterated its full-year guidance with Q1 figures in April 2026, including expectations for stable sales at constant currencies and a mid-single-digit percentage growth in EBITDA before special items. The scheduled Q2 disclosure will also provide fresh detail on free cash flow trends and net financial debt.

Litigation overhang and analyst views

Bayer continues to face a significant litigation overhang in the United States from Roundup weedkiller cases, where the company has recorded provisions running into the tens of billions of euros over recent years while continuing to defend a portion of claims in court. Recent U.S. case developments and any potential additional provisions will be a focal point for the Q2 update, especially for international investors comparing Bayer with peers such as BASF in the European chemicals space.

Analyst sentiment remains mixed: consensus data compiled by MarketScreener in late June 2026 points to a Hold rating on Bayer shares, with a spread of recommendations ranging from Buy to Sell and a wide dispersion in 12-month price targets. The latest Bayer analyst consensus shows focus on leverage reduction, litigation risk and portfolio optimization, including the future shape of the Consumer Health business.

How Bayer makes its money

Bayer generates revenue mainly through three divisions: Pharmaceuticals, Consumer Health and Crop Science, with the crop business including seeds, traits and crop protection products such as the Roundup herbicide line. Its pharmaceuticals portfolio spans cardiovascular, oncology and womens health therapies alongside ophthalmology treatments.

Where the stock trades today

Bayer shares most recently traded on Xetra at 28.40 euros as of 2026-06-29, 11:15, reflecting the companys position as a member of the DAX index in Frankfurt.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.